Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

Results from the Phase III ZENITH trial show that Winrevair lowered the risk of all-cause death, lung transplantation, and ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Three decades of data from the Global Burden of Disease Study were analyzed for trends in global, regional, and national ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) ...

The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

A new study from Thailand shows that a rapid peak in skin thickness progression in systemic sclerosis patients may predict ...

Treatments approved for PAH may reduce by half the risk of serious complications or death in patients with repaired ...